Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Drugging “undruggable” transcription factor drivers in cancer

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.04.16
Views: 1593

Dr John Bushweller - Unviersity of Virgina, Virginia, USA

Dr John Bushweller speaks with ecancertv at AACR 2016 about his efforts to target transcription factors as cancer therapy.

Transcription factors have historically been too transient to effectively control gene expression in tumour cells, but Dr Bushweller describes a novel technique to inhibit transcription factor fusion that has resulted in restoring normal gene expression to cells.

Gene alteration in situ is itself a hallmark of tumourigenesis, and Dr Bushweller reports that combination with activated kinase therapy may be able to limit cancer mutagenesis. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation